Related Experiment Video

Updated: May 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

JAK inhibitors suppress t(8;21) fusion protein-induced leukemia

M-C Lo1, L F Peterson, M Yan

  • 1Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA.

Leukemia
|July 2, 2013
PubMed

Insights

Targeting the JAK/STAT pathway with inhibitors like TG101209 shows promise for treating acute myeloid leukemia (AML) driven by the t(8;21) fusion protein. These JAK inhibitors effectively reduced leukemia cell growth and improved survival in preclinical models.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • The JAK/STAT pathway is frequently dysregulated in hematological malignancies, making it a target for cancer therapy.
  • The t(8;21) fusion protein AML1-ETO and its variant AE9a enhance JAK/STAT signaling by downregulating CD45, a key pathway regulator.
  • Targeting JAK/STAT signaling is a potential therapeutic strategy for t(8;21) acute myeloid leukemia (AML).

Purpose of the Study:

  • To investigate the therapeutic efficacy of JAK inhibitors in t(8;21) AML.
  • To evaluate the effects of TG101209 (JAK2-selective) and INCB18424 (JAK1/2-selective) on t(8;21) leukemia cells and in vivo models.

Main Methods:

  • Treatment of t(8;21) leukemia cells with JAK inhibitors TG101209 and INCB18424.
  • Assessment of cell proliferation and apoptosis.
  • In vivo studies using AE9a leukemia mouse models treated with TG101209.
  • Evaluation of tumor burden, survival, and leukemia-initiating potential in secondary recipients.

Main Results:

  • Both TG101209 and INCB18424 inhibited proliferation and induced apoptosis in t(8;21) leukemia cells.
  • TG101209 treatment in mice significantly reduced tumor burden and prolonged survival.
  • TG101209 impaired the leukemia-initiating capacity of AE9a leukemia cells in secondary recipients.

Conclusions:

  • JAK inhibitors demonstrate significant therapeutic potential for treating t(8;21) AML.
  • Targeting JAK/STAT signaling offers a promising strategy for AML therapy.
  • TG101209 shows efficacy in reducing tumor burden and improving survival in preclinical models of t(8;21) AML.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.